Combining ultraviolet (UV) phototherapy with the Janus kinase (JAK) inhibitor baricitinib (Olumiant) helped patients with ...

This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in ...

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating ...

Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Italy’s Alfasigma SpA in a ...

“[JAK inhibitors] have had a significant impact on [myelofibrosis] management,” Thaw and colleagues wrote. “It has been well established these drugs are able to induce spleen responses and reduce ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

Piclidenoson compared favorably to Otezla. There are several JAK inhibitors being investigated in phase II and phase III trials for moderate-to-severe psoriasis. They include the drugs tofacitinib and ...

post-marketing safety study of Pfizer's JAK inhibitor Xeljanz (tofacitinib) in rheumatoid arthritis before deciding whether to approve new indications for drugs in the class. That includes AbbVie ...

Limited clinical data is available advocating the use of jak-inhibitors as an effective treatment for autoimmune complications of PTPN2-deficiency. However, the mechanism of pathogenesis for these ...